Phase 1
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type

Drug Details

BBT-877 is a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis.

Study Purpose

This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

This drug has no clinical trials actively recruiting patients at this time.


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >